Inventory

9 Months Ended

Sep. 30, 2024

Inventory Disclosure [Abstract]

Inventory

Note 3 —Inventory

Upon FDA approval of YCANTH (VP-102) for the treatment of molluscum contagiosum on July 21, 2023, the Company began capitalizing the purchases of saleable inventory of YCANTH (VP-102) from suppliers. Inventory consisted of the following (in thousands):

	September 30,		December 31,
	2024		2023
Raw materials	$	1,208	$	420
Work in process		750		487
Finished goods		626		115
Total inventory	$	2,584	$	1,022